Cart mincart
home
Search Results

2017 FDA New Drug Approvals

by Instructor: Jill O'Donnell PharmD, BCPS, BCGP

$30.00

i 3.00 Hours

Course Overview

Keeping up with the approval of new medications is one of the many challenges of pharmacists and other healthcare providers. As an expert in the field of drug information, a pharmacist plays a vital role in educating patients and other healthcare providers on new medication options. In 2017, the FDA approved 46 new medications to treat a wide variety of disease states, including cancers, multiple sclerosis, and hepatitis C. Many of these new medications will significantly change the way we treat these diseases. This course provides an overview of newly approved medications and their importance to patient care. Specific drug characteristics, the clinical trials that were pivotal to the drugs’ approval, and therapeutic use of drugs are discussed. 

About the Course Author

Jill O’Donnell, PharmD, BCPS, BCGP is a clinical pharmacist trained in infectious disease and antimicrobial stewardship. She is a clinician, educator, and advocate of Antimicrobial Stewardship. Jill O'Donnell PharmD, BCPS, BCGP has declared that no conflict of interest, Relevant Financial Relationship or Relevant Non-Financial Relationship exists.

Get started now and your first course is free!

Become a member today and enjoy instant savings on all courses
GET CE-PRO

Accreditation Information

Certificates provided by accrediting body (3 Match)

  • Accreditation Council for Pharmacy Education

    3.00HOURS


    In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Type Activity: Knowledge
    Target Audience Designation: P
    ACPE Universal Activity Number: JA4008266-0000-21-263-H01-P

  • Accreditation Council for Pharmacy Education

    3.00HOURS

    In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Type Activity: Knowledge
    Target Audience Designation: T
    ACPE Universal Activity Number: JA4008266-0000-21-263-H01-T

  • Florida Board of Pharmacy

    3.00HOURS


    Florida Board of Pharmacy (CEBroker Provider #50-290)

    This module is approved for 3.0 contact hours.


Course Details

  • Course Code:

    REL-ACU-0-DRAP

  • Hours:

    3.00

  • Type:

    Online Course

  • Release Date:

    2019-10-01

  • Expiration Date:

    2022-09-05

  • Learning Objectives:

    Describe dosing and other caveats in therapy for first-in-class medications.; Discuss the therapeutic use for new drugs approved by the FDA in 2017.; Identify key clinical trials that brought these new medications to market.

  • Target Audience:

    The target audience for this course is: Pharmacists; Pharmacy Technicians; in the following settings: Acute Care Facility.

  • Course Delivery Method and Format:

    Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
    Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
    If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
    All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
    Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
    All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
    To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.

  • Accommodations:

    If you require special accommodations to complete this module, please contact Relias Customer Support here.

  • Disclosures:

    Expert Reviewers, Instructors, and Staff Writers disclosures will be listed above after the individuals' biographical paragraph. All other members involved within the planning of this educational activity have declared no conflict of interest exists when planning and developing this course.